Skip to main content

Table 2 G-BM and G-PBSC graft cell subset frequencies and cell doses

From: Superior GVHD-free, relapse-free survival for G-BM to G-PBSC grafts is associated with higher MDSCs content in allografting for patients with acute leukemia

 

Frequencies of graft cell subsets, (%), mean ± SD

 

Doses of graft cell subsets infused, 106 cells/kg of body weight, median (min–max)

 

G-BM (n = 49)

G-PBSC (n = 52)

P

G-BM (n = 49)

G-PBSC (n = 52)

P

CD3+

60 ± 10

68.0 ± 14.0

0.007

69.6(22–156)

285.8(68–467)

<0.001

CD3+CD4+

29 ± 8.7

35.0 ± 10.7

0.065

33(10–56)

139.3(45–257)

<0.001

CD4+CD45RA+

9.5 ± 5.7

13.1 ± 8.1

0.220

11(3–30)

51.3(16–121)

<0.001

CD4+CD45RO+

13.8 ± 7.7

16.2 ± 8.0

0.647

16(5–39)

63.6(16–150)

<0.001

CD3+CD8+

26.6 ± 7.4

27.9 ± 9.2

0.297

30(25–59)

111.8(28–265)

<0.001

CD8+CD45RA+

19.6 ± 6.6

20.5 ± 7.6

0.625

22(11–60)

79.0(20–189)

<0.001

CD4+/CD8+

1.04 ± 0.5

1.12 ± 0.5

0.967

   

CD19+

12.3 ± 5.0

12.7 ± 6.0

0.659

14(5–42)

48.5(12–90)

<0.001

CD3−CD56+

10.0 ± 7.0

7.0 ± 8.9

0.144

12(6–38)

27.9(3–76)

<0.010

Treg

3.1 ± 3.2

2.3 ± 2.0

0.192

3.0(1.5–6.7)

8.6(3.6–12.6)

<0.010

MDSCs

0.66 ± 0.23

0.40 ± 0.19

<0.01

3.9(1.4–7.3)

3.5(1.7–6.0)

0.045

  1. CD3+ cell and subsets, CD19+ cell, and CD3−CD56+ cell frequencies are shown as percentage of the lymphocytes, CD4+CD25+FOXP3+ Treg frequencies are shown as percentage of CD3+CD4+ cells, and MDSC frequencies are shown as percentage of total nucleated cells